High prevalence of interstitial lung abnormalities in middle-aged never-smokersShow others and affiliations
2023 (English)In: ERJ Open Research, E-ISSN 2312-0541, Vol. 9, no 5Article in journal (Refereed) Published
Abstract [en]
Background Interstitial lung abnormalities (ILA) are incidental findings on chest computed tomography (CT). These patterns can present at an early stage of fibrotic lung disease. Our aim was to estimate the prevalence of ILA in the Swedish population, in particular in never-smokers, and find out its association with demographics, comorbidities and symptoms. Methods Participants were recruited to the Swedish CArdioPulmonary BioImage Study (SCAPIS), a population-based survey including men and women aged 50-64 years performed at six university hospitals in Sweden. CT scan, spirometry and questionnaires were performed. ILA were defined as cysts, groundglass opacities, reticular abnormality, bronchiectasis and honeycombing. Findings Out of 29 521 participants, 14 487 were never-smokers and 14 380 were men. In the whole population, 2870 (9.7%) had ILA of which 134 (0.5%) were fibrotic. In never-smokers, the prevalence was 7.9% of which 0.3% were fibrotic. In the whole population, age, smoking history, chronic bronchitis, cancer, coronary artery calcium score and high-sensitive C-reactive protein were associated with ILA. Both ILA and fibrotic ILA were associated with restrictive spirometric pattern and impaired diffusing capacity of the lung for carbon monoxide. However, individuals with ILA did not report more symptoms compared with individuals without ILA. Interpretation ILA are common in a middle-aged Swedish population including never-smokers. ILA may be at risk of being underdiagnosed among never-smokers since they are not a target for screening.
Place, publisher, year, edition, pages
EUROPEAN RESPIRATORY SOC JOURNALS LTD , 2023. Vol. 9, no 5
National Category
Respiratory Medicine and Allergy
Identifiers
URN: urn:nbn:se:liu:diva-198872DOI: 10.1183/23120541.00035-2023ISI: 001075451800001PubMedID: 37753274OAI: oai:DiVA.org:liu-198872DiVA, id: diva2:1809185
Note
Funding Agencies|Swedish Heart and Lung Foundation; Knut and Alice Wallenberg Foundation; Swedish Research Council; VINNOVA (Swedens Innovation Agency); University of Gothenburg Hospital; Sahlgrenska University Hospital; Karolinska Institutet Hospital; Karolinska University Hospital; Linkoping University; Linkoping University Hospital; Lund University Hospital; Skane University Hospital; Umea University Hospital; Umea University; Uppsala University; Uppsala University Hospital
2023-11-022023-11-022024-04-22